GOLDACRE DEVELOPMENTS LIMITED

Company number 05668772 ·

Active

Net assets, total assets & total liabilities 2016 – 2025

  • Total assets
  • Net assets
  • Total liabilities
-£1.5m -£1m -£500k £0 £500k £1m £1.5m 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Total assets 2016: £1,353,208 Total assets 2017: £1,351,299 Total assets 2018: £1,347,373 Total assets 2022: £358,190 Total assets 2023: £350,088 Total assets 2024: £361,919 Total assets 2025: £349,441 Total assets Net assets 2016: £177,890 Net assets 2017: £202,555 Net assets 2018: £209,749 Net assets 2019: £209,705 Net assets 2020: £219,791 Net assets 2021: £234,694 Net assets 2022: £249,496 Net assets 2023: £264,623 Net assets 2024: £280,421 Net assets 2025: £301,666 Net assets Total liabilities 2016: -£1,478,822 Total liabilities 2017: -£1,449,982 Total liabilities 2018: -£1,423,562 Total liabilities 2019: -£107,672 Total liabilities 2020: -£88,172 Total liabilities 2021: -£72,172 Total liabilities 2022: -£60,172 Total liabilities 2023: -£53,293 Total liabilities 2024: -£58,626 Total liabilities 2025: -£44,903 Total liabilities

Figures extracted from filed accounts. Hover a point for the exact value.

Employees 2024 – 2025

0 0 0 0 1 1 1 1 2 2024 2025 2024: 2 2025: 2

Average employees, from filed accounts. Hover a point for the exact figure.

Balance sheet by year 10 years

Latest accounts (2025-12-31): Audit exempt.

Year ending Total assets Total liabilities Net assets Cash Turnover Profit Employees
2025-12-31 £349,441 -£44,903 £301,666 £611 2
2024-12-31 £361,919 -£58,626 £280,421 £10,724 2
2023-12-31 £350,088 -£53,293 £264,623 £336
2022-12-31 £358,190 -£60,172 £249,496 £9,360
2021-12-31 -£72,172 £234,694 £1,537
2020-12-31 -£88,172 £219,791 £364
2019-12-31 -£107,672 £209,705 £7,422
2018-12-31 £1,347,373 -£1,423,562 £209,749 £4,135
2017-12-31 £1,351,299 -£1,449,982 £202,555 £8,061
2016-12-31 £1,353,208 -£1,478,822 £177,890 £9,970

Profit and employee figures are captured from accounts filed from August 2026 onwards, where the accounts disclose them.